Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Pompeo Hints At ‘Broader’ Ban on Chinese Apps After Trump’s Executive Orders Targeting TikTok and WeChat
Trending in China: Merchants and Netizens Forced to Pick Sides in Fight Between Delivery Firms
Baidu-Backed Video Streamer iQiyi Probed by U.S. Regulator After Short Seller’s Report
AI Unicorn SenseTime Is Said to Mull Hong Kong, China IPO
Huawei Copies Korean Rivals by Manufacturing Own Display Driver Integrated Chips
JOYY’s Livestreaming Revenue Up 40% in Second Quarter of 2020
Trending in China: ‘Mukbangs’ Under Fire in China Amid High Level Food Waste Campaign
Trending in China: How Will the Chinese Diaspora Survive a WeChat Ban In U.S.?
Online Platform JD.com Buys into Bricks and Mortar Convenience Store Chain
China Unicom Profits Rise in First Half, Stock Soars
ByteDance in Talks with Indian Conglomerate Over TikTok Amid Layoff Fears
Alibaba’s Zhang Yong Tops 2020 Forbes China Best CEOs List
Trending: Family Feud Raises Big Questions Over Succession in China’s Multi-Million “Family” Businesses
Shanghai-Listed Foxconn Internet’s Cloud Service Sales Up 4% in First Half of 2020
U.S.-Listed Chinese Companies Nio and Huya Have Something to Cheer About
Apple Edges Huawei Out of No. 1 in Quarterly Tablet Shipments
Chinese Finance Platform Lufax Files for U.S. IPO of up to $3 Billion
China Mainland Leads U.S. in Fortune Global 500 Companies But Trails in Profitability
Trending in China: Tencent – Fighting Youth Unemployment or Enemy of Older Workers?
Tencent Pushes for Merger That Would Create $10 Billion Chinese Twitch
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise

By Ding Yi / Jul 03, 2020 04:35 PM / Business & Tech

Photo: Visual China

Photo: Visual China

German pharmaceutical firm Boehringer Ingelheim (BI) has launched its External Innovation Hub in Shanghai in a bid to harness China’s expertise in life science innovation to power its global drug discovery and development chain.

A big feature of the hub is that the facility adopts a so-called “3-in-1” system, meaning that it will integrate BI’s external-facing functions including Research Beyond Borders (RBB), Business Development & Licensing (BD&L) and BI Venture Fund (BIVF) under one roof, according to a statement by the company Thursday.

RBB is a global research unit BI likens to a “radar” that can detect the next big wave of innovation in life science. The BD&L team and the BIVF together play a role in turning scientific approaches into business ideas.

The hub will also create various partnerships to help BI sharpen its core therapeutic capabilities, meet urgent medical needs and possibly identify therapeutic areas for future strategic investment.

The launch of the Shanghai hub comes three months after BI unveiled a plan to open a digital lab in July in the same city, with plans to recruit dozens of experts in digital healthcare to help develop medicines and therapies for the Chinese market.

In a separate post published on its public WeChat account, BI said that it plans to invest 451 million euros ($508 million) over the next five years in China, a market it entered more than two decades ago.

Since its entry into China, BI has forged partnerships with multiple local academic institutions and companies in the country including Tsinghua University and Peking University, the company said.

In recent years, foreign drugmakers have increased investment in China, where the government aims to grow the healthcare industry to 8 trillion yuan ($1.1 trillion) by the end of 2020 and 16 trillion yuan by 2030

Contact reporter Ding Yi (yiding@caixin.com)

Related: German Drugmaker BI to Establish Digital Lab in Shanghai


Share this article
Open WeChat and scan the QR code